Larimar Therapeutics Reports Positive Friedreich's Ataxia Treatment Data, Adjusts Dosing Regimen for Anaphylactic Risks
ByAinvest
Thursday, Nov 6, 2025 6:05 am ET1min read
LRMR--
Larimar Therapeutics has reported promising long-term data from its open-label study on Friedreich's ataxia, highlighting consistent improvements across four key clinical outcomes and increased skin frataxin levels. The company is adjusting its dosing regimen to mitigate anaphylactic risks, aiming for a Biologics License Application by Q2 2026. Larimar's financial metrics indicate a challenging environment with a focus on strategic development and regulatory progress.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet